Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy. Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.
Study Type
OBSERVATIONAL
Enrollment
900
Drug interventions have been done in previous clinical studies
three years mortality
Mortality rate of patients treated with thymosin α1 or placebo within 3 years
Time frame: 3 years
Recurrence rate of sepsis
Percentage of recurrent sepsis within 5 years of discharge sepsis patients
Time frame: 5 years
one year mortality
Mortality rate of patients treated with thymosin α1 or placebo within 1 year
Time frame: 1 year
Five years mortality
Mortality rate of patients treated with thymosin α1 or placebo within 5 years
Time frame: 5 years
short form 36 questionnaire
Quality of life of sepsis patients after 1 year of thymosin α1 or placebo treatment
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.